Trials
5 active
5 in total · 5 in the EU
What this is
- How it works
- Blocks PI3K, an enzyme that passes growth signals inside cells. Mostly used against cancer.-lisib: PI3K inhibitors WHO name stem
- How it’s given
- “IOA-244: 80 mg (corresponding to 72 mg roginolisib) Ruxolitinib: up to 25 mg BD”In the company’s words, NCT06887803 on ClinicalTrials.gov
- Tested for
- Uveal Melanoma (2 trials), Ocular Melanoma, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC, Myelofibrosis (MF), Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC and 1 more
- Main trialPhase 2
- “The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma. The main questions it aims to answer are: Does roginolisib extend overall survival compared to standard treatment? How does dosing of roginolisib impact quality of life compared to standard treatment?”In the company’s words, NCT06717126 on ClinicalTrials.gov
- Other names
- IOA-244
Other drugs for Uveal Melanoma
- DarovasertibIDEAYA Biosciences · Phase 3
- AU-011Aura Biosciences · Phase 3
- RP2Replimune, Inc. · Phase 2/3
- Melphalan/HDSDelcath Systems Inc. · Phase 3
- EB-DTKN-401Beijing Biotech · Phase 1/2
- DYP688Novartis Pharmaceuticals · Phase 1/2
Coming up3
- Jan 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Mar 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Dec 2027 | A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma | |
| Phase 1/2Active, not recruiting | Jan 2027 | A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients | |
| Phase 1/2Recruiting | Mar 2028 | A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors | |
| Phase 1Active, not recruiting | 13 Dec 2023 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | |
| Phase 1/2Authorised | not given | PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026